SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
453.60    3.80 (0.84%)
Bid:
452.90
Ask:
453.20
Spread: 0.30 (0.066%)
Market Cap: £11.41b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Q1 Trading Update

18 Apr 2019 07:00

RNS Number : 5559W
Rentokil Initial PLC
18 April 2019
Β 

Β 

RENTOKIL INITIAL PLC (RTO)

FIRST QUARTER TRADING UPDATE

18 April 2019

Β 

(Β£m)

Β 

Q1 2019

Growth

Β 

Β 

AER

AER

CER

Ongoing Revenue1

Β 

603.6

10.6%

8.9%

Revenue

Β 

607.4

10.3%

8.6%

Β 

Overview

Trading has started well across our businesses in Q1 with Ongoing Revenue1 increasing by 8.9%, of which 4.0% was Organic Revenue2 growth (Q1 2018: 3.2%, FY 2018: 3.7%) and 4.9% was from acquisitions.

Ongoing Revenue in Pest Control grew by 12.0%, 5.0% Organic (Q1 2018: 4.7%), with good performances being delivered across both Growth and Emerging markets, which rose by 12.1% and 11.5% respectively. Hygiene has made a very positive start to the year, with Ongoing Revenue growth of 7.2% and Organic Revenue growth of 4.3% (Q1 2018: 1.8%). Ongoing Revenue in our Protect & Enhance markets was in line with Q1 2018.

M&A

​We signed eight acquisitions in Q1, four in Pest Control (primarily in North America and Latin America) and four in Hygiene, with combined annualised revenues of c. Β£29m in the year prior to purchase. We are encouraged about our prospects for further M&A this year and our pipeline of value-enhancing opportunities is strong. Our guidance for M&A spend in 2019 remains in the range of Β£200m to Β£250m. Β 

Pension Scheme and Funding

In December 2018 the Company reached agreement for a bulk annuity insurance 'buy-in' for its UK Defined Benefit Pension scheme ("the Scheme") in contemplation of a full 'buy-out' which is expected to complete in early 2020. Good progress towards buy-out is being made andΒ we now anticipate a pre-tax cash surplus of c. Β£40m will be returned to the Company on completion.

Ahead of the refinancing of our €500m bond maturing in September this year, we are intending to hold a non-deal, bond investor education roadshow in London, France, Germany, the Netherlands, Nordics and Asia. We will release further details in due course.

​Commenting on today's announcement Andy Ransom, Chief Executive, said:

"We have had a good start to 2019 and I'm pleased with our performance in the first three months of this year. I am confident of another year of successful growth for the Company, in line with market expectations."

Β 

Enquiries:

Β 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

07811 270734

Β 

Β 

Β 

Β 

Media:

Malcolm Padley

Rentokil Initial plc

07788 978199

Β 

Β 

Β 

Β 

1Ongoing Revenue represents the performance of the continuing operations of the Group (including acquisitions) after removing the effect of disposed or closed businesses.

Β 

2Organic Revenue represents the growth in Ongoing Revenue excluding the effect of businesses acquired during the year. Acquired businesses are included in organic measures in the year following acquisition, and the comparative period is adjusted to include an estimated full year performance for growth calculations.

Β 

AER - actual exchange rates; CER - constant 2018 exchange rates

Β 

This announcement contains statements that are, or may be, forward-looking regarding the Group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure Guidance and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
TSTZMGMDRNMGLZM
Date   Source Headline
19th Jul 20177:00 amRNSAppointment of Non-Executive Director
30th Jun 20178:33 amRNSCompletion of Joint Venture with Haniel
27th Jun 20175:21 pmRNSHolding(s) in Company
26th Jun 20174:54 pmRNSHolding(s) in Company
8th Jun 201711:40 amRNSFurther re Joint Venture with Haniel
7th Jun 20179:41 amRNSDirector Declaration
17th May 20175:02 pmRNSHolding(s) in Company
10th May 20174:31 pmRNSResult of AGM
10th May 20174:03 pmRNSHolding(s) in Company
10th May 201711:49 amRNSAppointment of Senior Independent Director
9th May 20175:51 pmRNSHolding(s) in Company
4th May 20174:44 pmRNSDirector/PDMR Shareholding
26th Apr 20174:27 pmRNSDirector/PDMR Shareholding
25th Apr 20175:58 pmRNSDirector/PDMR Shareholding
21st Apr 20177:00 amRNSRentokil awarded Queen's Award for Enterprise
19th Apr 20177:00 amRNSQ1 Trading Update
5th Apr 201710:43 amRNSAnnual Financial Report
31st Mar 20174:18 pmRNSTotal Voting Rights
30th Mar 20173:25 pmRNSBlock listing Interim Review
22nd Mar 20176:10 pmRNSHolding(s) in Company
9th Mar 20173:06 pmRNSAdditional Listing
28th Feb 20177:00 amRNSRentokil - Leading Pest Control Company in India
24th Feb 20172:37 pmRNSHolding(s) in Company
23rd Feb 20177:00 amRNSFinal Results
7th Feb 20177:00 amRNSAcquisition of Allgood Pest Solutions
29th Dec 20164:30 pmRNSDirector/PDMR Shareholding
16th Dec 20162:59 pmRNSHolding(s) in Company
16th Dec 20162:02 pmRNSHolding(s) in Company
16th Dec 20167:00 amRNSJoint venture with Haniel
7th Dec 20165:47 pmRNSHolding(s) in Company
7th Dec 20167:00 amRNSHolding(s) in Company
18th Nov 20161:15 pmRNSDirector Declaration
11th Nov 20165:30 pmRNSHolding(s) in Company
11th Nov 20165:10 pmRNSTotal Voting Rights
3rd Nov 20161:01 pmRNSDirector Declaration
19th Oct 20167:00 amRNSQ3 Trading Update
6th Oct 20162:58 pmRNSAdditional Listing
6th Oct 201612:31 pmRNSDirector Declaration
4th Oct 20169:49 amRNSDirector Declaration
30th Sep 20162:10 pmRNSTotal Voting Rights
29th Sep 20167:00 amRNSAdditional Listing
26th Sep 20164:48 pmRNSDirector/PDMR Shareholding
22nd Aug 20164:56 pmRNSHolding(s) in Company
28th Jul 20167:00 amRNSHalf Yearly Report
27th Jul 20167:00 amRNSCollaboration with Google and PA Consulting Group
7th Jul 20167:00 amRNSAcquisition, CDC Contract Win and Trading Update
29th Jun 20167:00 amRNSDirectorate Change
29th Jun 20167:00 amRNSDirector/PDMR Shareholding
22nd Jun 20165:27 pmRNSHolding(s) in Company
17th May 20165:06 pmRNSDirector/PDMR Shareholding - Replacement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.